RANJAN GOLI: Open Payments
NPI 1043835937 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,327 in 60 payments from 25 companies in 2025. Trend: 2023 $400 · 2024 $676 · 2025 $1,327
Food & beverage: $1,327
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $219 |
| Merck Sharp & Dohme LLC | 6 | $150 |
| Novartis Pharmaceuticals Corporation | 4 | $93 |
| Celgene Corporation | 4 | $86 |
| E.R. Squibb & Sons, L.L.C. | 4 | $85 |
| Blueprint Medicines Corporation | 3 | $79 |
| Exelixis Inc. | 3 | $71 |
| BeOne Medicines USA, Inc. | 4 | $68 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
Products named: KEYTRUDA, IMFINZI, REBLOZYL, AYVAKIT, CABOMETYX, Enhertu, OPDIVO, PLUVICTO.
Industry payments across AL — which companies pay providers there.
